Niraparib: all 158 studies that test it

Page 2 of 2. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.

• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2
• Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2
• Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and DostarlimabTerminatedNCT04779151Phase 2
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
• Niraparib Combined With Radiotherapy in rGBMStatus unknownNCT04715620Phase 2
• Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasActive, not recruitingNCT04701307Phase 2
• Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentStatus unknownNCT04679064Phase 3
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingNCT04577833Phase 1
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
• Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingNCT04507841Phase 2
• Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingNCT04502602Phase 1
• A Study of Niraparib in Patients With Relapsed Ovarian CancerCompletedNCT04392102Phase 2
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04376073Phase 2
• Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant SettingCompletedNCT04284852Phase 2
• ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian CancerTerminatedNCT04267939Phase 1
• Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)CompletedNCT04240106Phase 2
• Phase I Study of SYD985 With Niraparib in Patients With Solid TumorsCompletedNCT04235101Phase 1
• Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian CancerStatus unknownNCT04217798Phase 2
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerTerminatedNCT04159155Phase 2/3
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian CancerWithdrawnNCT04149145Phase 1
• Trial of Maintenance With Niraparib- Uterine Serous CarcinomaCompletedNCT04080284Phase 2
• Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerActive, not recruitingNCT04068753Phase 2
• A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3
• A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingNCT03945721Phase 1
• Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based ChemotherapyCompletedNCT03945084Phase 2
• CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1
• Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) MutationStatus unknownNCT03925350Phase 2
• A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1
• Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerTerminatedNCT03891615Phase 1
• Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2
• Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyActive, not recruitingNCT03830918Phase 1/2
• Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.CompletedNCT03752216Phase 4
• A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3
• Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3
• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
• Niraparib in Patients With Pancreatic CancerCompletedNCT03601923Phase 2
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
• The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1
• A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Phase 3
• Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)CompletedNCT03425201Phase 1/2
• Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerActive, not recruitingNCT03368729Phase 1/2
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesTerminatedNCT03209401Phase 1
• Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
• Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)CompletedNCT03076203Phase 1
• Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingNCT03016338Phase 2
• A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)CompletedNCT02924766Phase 1
• A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsTerminatedNCT02826512Phase 2
• Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With CancerCompletedNCT02476552Phase 1
• Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
• A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)WithdrawnNCT01244009Phase 2
• MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedNCT01227941Phase 1
• A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)TerminatedNCT01226901Phase 1
• A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1

← Niraparib overview